Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVT 302 with or without nicotine replacement therapy on craving and withdrawal in healthy male smokers
2007-006236-63Phase 2Completed
- Sponsor
- Evotec SE
- Start
- Nov 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sembragiline in nicotine dependence (4 arms), sponsored by Evotec SE. Primary endpoint: Nicotine craving and urging. Started Nov 2007; status: completed.
02
Drugs
sembragiline
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on 2007-006236-63.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006236-63.